shazdancer
Frequent Contributor (1K+ posts)
Member # 1436
posted
The Lancet Infectious Diseases Volume 7, Issue 1 , January 2007, Pages 68-78
Forum Anti-infective research and development--problems, challenges, and solutions
John S Bradley, Robert Guidos, Steve Baragona, John G Bartlett, Ethan Rubinstein, George G Zhanel, Michael D Tino, David L Pompliano, Frank Tally, Praveen Tipirneni, Glenn S Tillotson, John H Powers and Glenn S Tillotson
Retrieved online.
This group from IDSA is decrying the fact that many of the big pharmaceuticals are not developing new antibiotics.
quote:We identified several obstacles to antibiotic development.2 Anti-infective drug products are less profitable than other types of medicines, particularly those for chronic conditions.
Furthermore, once a new antibiotic is finally approved, infectious disease physicians add an additional financial disincentive and urge our general practice colleagues to refrain from using it to help reduce the development of resistance.
As a result, many major pharmaceutical companies have decided to focus their research and development efforts elsewhere, leaving the pipeline in this essential field dangerously dry.
One writer suggested working on better immune-support techniques, better dosing times, and combinations therapy...
quote:Lack of new antibiotics requires re-evaluating and re-investing in monoclonal antibodies, bacteriophages, probiotics, and ways to augment innate immunity.
With few new antibiotics in the pipeline, perhaps we need to go back and re-evaluate our dosing schedules, durations of treatment, and how and when to use combination therapy to achieve clinical success and prevent resistance from occurring.
Posts: 1558 | From the Berkshires | Registered: Jul 2001
| IP: Logged |
Truthfinder
Frequent Contributor (1K+ posts)
Member # 8512
posted
Good post.
Well, this does help explain why there's not a lot of research being done on new abx, and why the drug companies aren't particularly interested in the whole chronic Lyme problem, as least from the perspective of creating new abx.
Funny they didn't even mention nano-technology.
What's that other thing called where they use specific, ``genetically engineered'' viruses to kill certain other organisms? Gosh, I can't think of the word!
Tracy
-------------------- Tracy .... Prayers for the Lyme Community - every day at 6 p.m. Pacific Time and 9 p.m. Eastern Time � just take a few moments to say a prayer wherever you are�. Posts: 2966 | From Colorado | Registered: Dec 2005
| IP: Logged |
clairenotes
Frequent Contributor (1K+ posts)
Member # 10392
posted
Quote:
"With few new antibiotics in the pipeline, perhaps we need to go back and re-evaluate our dosing schedules, durations of treatment, and how and when to use combination therapy to achieve clinical success and prevent resistance from occurring.***"
Yes... the answer may lie in the sequencing.
[ 05. January 2007, 12:16 PM: Message edited by: clairenotes ]
Posts: 1111 | From Colorado | Registered: Oct 2006
| IP: Logged |
Greatcod
Unregistered
posted
The real deal is that most often antibiotics are used for short periods of time, and that diminishes their bottom line potential. Same for diseases that plague the third world; the victims don't have the money to pay for medicines. No profit, no drug. A serious weak link in the arguement for the infalibility of market systems.
IP: Logged |
clairenotes
Frequent Contributor (1K+ posts)
Member # 10392
posted
Quote:
"A serious weak link in the arguement for the infalibility of market systems."
Very serious!!
Claire
Posts: 1111 | From Colorado | Registered: Oct 2006
| IP: Logged |
The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:
The
Lyme Disease Network of New Jersey 907 Pebble Creek Court,
Pennington,
NJ08534USA http://www.lymenet.org/
UBBFriend: Email this page to someone!
Printer-friendly view of this topic